|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||464.59 - 484.06|
|52-week range||372.50 - 564.74|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||49.24|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis. By replacing Lyme disease detection with detection of leishmaniosis, a more prevalent endemic disease in certai
WESTBROOK, Maine, November 01, 2023--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.
WESTBROOK, Maine, October 05, 2023--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 third quarter results for Wednesday, November 1, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.